1. Borgna‑PignattiC, CappelliniMD, De StefanoP, Del VecchioGC,
Forni GL, Gamberini MR, et al. Cardiac morbidity and
mortality in deferoxamine‑or deferiprone‑treated patients with thalassemia major. Blood 2006;107:3733‑7.
2. Moayedi Esfahani BA, Reisi N, Mirmoghtadaei M. Evaluating
the safety and efficacy of silymarin in ß‑thalassemia patients:
A review. Hemoglobin 2015;39:75‑80.
3. Raškovic A, Stilinovic N, Kolarovic J, Vasovic V, Vukmirovic S,
Mikov M. The protective effects of silymarin against
doxorubicin‑induced cardiotoxicity and hepatotoxicity in rats.
Molecules 2011;16:8601‑13.
4. Aniss HA, Said AE, El-Sayed IH, Adly C. Doxorubicin-induced
cardiotoxicity in mice; protection by silymarin. Egypt J Hosp
Med 2012;48:383-93.
5. ZholobenkoA, Modriansky M. Silymarin and its constituents
in cardiac preconditioning. Fitoterapia 2014;97:122‑32.
